Abstract
The success of personalized medicine cannot be measured in dollars alone. The improvement in healthcare and quality of life with reduction of disease burden will have an impact on all aspects of human life with economic benefits. A discussion of financial aspects, of personalized medicine, however, is important for two reasons: (1) pharmaceutical companies would like to know if it would be profitable; and (2) healthcare providers would like to know if it is affordable. Development of personalized medicine would also affect the pharmaceutical markets, which will be discussed later in this chapter. A more detailed description of the commercial aspects of personalized medicine including markets and profiles of companies involved in developing various relevant technologies can be found in a special report on this topic (Jain 2009g).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jain KK (2009a) Molecular diagnostics: technologies, markets and companies. Jain PharmaBiotech, Basel, Switzerland.
Jain KK (2009g) Personalized medicine: scientific and commercial aspects. Jain PharmaBiotech, Basel, Switzerland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jain, K.K. (2009). Economics of Personalized Medicine. In: Textbook of Personalized Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0769-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0769-1_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0768-4
Online ISBN: 978-1-4419-0769-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)